Bio-Techne Q2 Adj EPS $0.40 Misses $0.41 Estimate, Sales $272.60M Miss $277.53M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne (NASDAQ:TECH) reported Q2 adjusted EPS of $0.40, missing the consensus estimate of $0.41, and sales of $272.60M, missing the estimate of $277.53M. This represents a 14.89% decrease in EPS and a 0.37% increase in sales from the same period last year.
February 01, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bio-Techne's Q2 earnings and sales missed estimates, with a significant decrease in EPS compared to last year but a slight increase in sales.
Missing both EPS and sales estimates, especially with a notable year-over-year decrease in EPS, is likely to negatively impact investor sentiment and the stock price in the short term. The slight increase in sales year-over-year may not be sufficient to offset the negative impact of the earnings miss.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100